Target Name: ANKRD9
NCBI ID: G122416
Review Report on ANKRD9 Target / Biomarker Content of Review Report on ANKRD9 Target / Biomarker
ANKRD9
Other Name(s): ANKRD9 variant 2 | ankyrin repeat domain 9 | ANKR9_HUMAN | Ankyrin repeat domain 9 | Ankyrin repeat domain-containing protein 9 | Ankyrin repeat domain 9, transcript variant 2

ANKRD9: The ANKRD9 Variant 2 Drug Target and its Potential Implications

The ANKRD9 gene, located on chromosome 16, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The ANKRD9 gene has four splice variants, ANKRD9-V1, ANKRD9-V2, ANKRD9-V3, and ANKRD9-V4. In this article, we will focus on the ANKRD9-V2 variant, which has been studied extensively in the context of neurodegenerative diseases.

Expression of ANKRD9 in Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and their respective neural pathways. The ANKRD9 gene has been shown to be involved in the development and progression of these diseases.

Studies have shown that ANKRD9 is expressed in the brains of individuals with neurodegenerative diseases, and that it is involved in the development of neurofibrillary tangles and neurodegeneration. Additionally, ANKRD9 has been shown to play a role in the regulation of neurotransmitter systems, which are critical for the functioning of the brain cells.

Ankrd9-V2: A Potential Drug Target

The ANKRD9-V2 variant is a splicing error that results in the substitution of a specific amino acid residue for another. This error has been shown to contribute to the misfolding of ANKRD9 protein and the formation of neurofibrillary tangles in the brain.

The ANKRD9-V2 variant has been shown to be associated with the misfolding of ANKRD9 protein and the development of neurodegenerative diseases. This suggests that ANKRD9-V2 may be a potential drug target for the treatment of neurodegenerative diseases.

Ankrd9-V2 Targets: Potential Therapies

Several studies have shown that ANKRD9-V2 is involved in the regulation of the production of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to brain cells and contribute to the development of neurodegenerative diseases.

The ANKRD9-V2 variant has been shown to interact with several protein partners, including 尾-secretase (BACE1) and heat shock protein (HSP70). These interactions suggest that ANKRD9-V2 may be a target for drugs that can modulate the activity of these proteins.

One potential approach to treating neurodegenerative diseases may be to target ANKRD9-V2 and modulate the activity of these associated proteins. This could involve the use of small molecules, such as drugs that can modulate the activity of BACE1 or HSP70, or antibodies that can specifically target ANKRD9-V2.

Conclusion

The ANKRD9 gene has been identified as a potential drug target and biomarker for neurodegenerative diseases. The ANKRD9-V2 variant has been shown to contribute to the misfolding of ANKRD9 protein and the development of neurodegenerative diseases. Targeting ANKRD9-V2 and modulating the activity of associated proteins, such as BACE1 and HSP70, may be a promising approach to the treatment of neurodegenerative diseases. Further research is needed to

Protein Name: Ankyrin Repeat Domain 9

Functions: Substrate receptor subunit of a cullin-RING superfamily E3 ligase complex (CUL5-based E3 ubiquitin ligase complex) which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:30293565). Depending of the metabolic state of the cell, promotes the proteasomal degradation of IMPDH2, the rate-limiting enzyme in GTP biosynthesis or protects IMPDH2 by stabilizing IMPDH2 filaments assembly (PubMed:30293565, PubMed:31337707). Implicated in different cellular processes, like copper homeostasis and cell proliferation (PubMed:24522796, PubMed:30293565)

The "ANKRD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ANKS1A | ANKS1B | ANKS3 | ANKS4B | ANKS6 | ANKUB1 | ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3